MedTrace Logo

The Efficacy and Tolerability of Canagliflozin in Healthy Individual

NCT06301529 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-19

No results posted yet for this study

Summary

The primary objective is to measure the effects that canagliflozin intervention has on reducing average glucose in healthy individuals.

The secondary objective is to assess the tolerability and side effects and urinary glucose excretion following the pulsatile dosing protocol.

Conditions

  • Healthy Aging

Interventions

DRUG

Invokana Pill

100 mg and 150 mg doses, taken every day and every-other day, respectively.

Sponsors & Collaborators

  • AgelessRx

    lead INDUSTRY

Principal Investigators

  • James P Faber · Institutional Review Board (IRB) of the Institute of Regenerative and Cellular Medicine (IRCM)

  • Sajad Zalzala, MD · AgelessRx

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-12
Primary Completion
2024-06-29
Completion
2024-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301529 on ClinicalTrials.gov